AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04940390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Description: Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
Study NCT04940390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for STS101
Study NCT05458102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Administered orally
Study NCT05458102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Administered orally
Study NCT05458102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Administered orally
Study NCT06409351 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: Please refer to arm descriptions
Study NCT06409351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Please refer to arm descriptions
Study NCT05458102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Administered orally
Study NCT05428436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550 ICF
Description: BI 1015550 intended Commercial Formulation (iCF)
Study NCT05428436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550 TF2
Description: BI 1015550 trial formulation 2 (TF2)
Study NCT06639321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Ventricular Assist System
Description: Percutaneous Ventricular Assist System provides intraoperative circulatory support during high-risk PCI.
Study NCT06639321 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal membrane oxygenation (ECMO)
Description: ECMO provides intraoperative circulatory support during high-risk PCI.
Study NCT06640010 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT06637982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ridge splitting with the use of allograft and pericardium membrane
Description: ridge splitting with the use of allograft and pericardium membrane
Study NCT06637982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ridge splitting with the use of extended platelet rich fibrin
Description: ridge splitting with the use of extended platelet rich fibrin
Study NCT06641648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK cell
Description: Drug: Donor NK cells injection is a non-genetically modified natural killer cells therapy derived from a healthy donor.
Study NCT06637956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG)
Description: Received 1 mg of nitroglycerin intranasally two minutes prior to laryngoscopy and intubation
Study NCT06038981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of 1g tranexamic acid intravenous bolus, after anesthesia was introduced
Description: The systemic use of tranexamic acid (TXA) has been shown to be effective in many types of surgery, reducing the incidence of post-operative bleeding and thereby reducing the rate of reoperation.~To evaluate if TXA systemic administration reduces postoperative blood loss in bariatric surgeries (sleeve gastrectomy operation)
Study NCT06198127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combination of core stability exercises and kinesio-taping
Description: the patient in the experimental group will receive the core stability exercises with kinesiology taping on trunk stabilizer muscles. the time of intervention was 30 minutes per day. The exercises such as Abdominal draw-in with a double knee to chest, Trunk twist while sitting on a medicine ball, Lying in a supine position on bed and rotating the trunk from side-to-side, Bridging exercises, the I-shaped elastic KT will apply to the four trunk muscles from their insertion to their origin: Kinesio-taping is used on global muscles such as Rectus abdominis, External obliques, Erector spinae, Quadratus lumborum. Kinesio-taping will 1 inch wide and apply on muscles for 1 to 2 days then remove for 24 hours then again apply a new one. The tension will be 10 to 15% and tape will apply on muscles which will be stretched by maintaining a posture.
Study NCT06198127 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stability exercises
Description: After the baseline assessment, the patient in the control group will receive the core stability exercises with kinesio-taping on trunk stabilizer muscles. Time of rehabilitation will be 30 minutes per subject and four days per week. In first few minutes, the subject will be explained her/his task Subject will execute the exercises such as Abdominal draw-in with a double knee to chest 10- 15 times. Trunk twist while sitting on a medicine ball 10- 15 times. Lying in a supine position on bed and rotating the trunk from side-to-side 10- 15 times. Lying in a supine position on a mat and pulling upper and lower limbs upward 10- 15 times. Bridging exercises 10- 15 times, Deep Breathing and Wheelbarrow.
Study NCT05336123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha Yoga
Description: Weekly hatha yoga classes lasting 10 weeks.
Study NCT05336123 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Weekly health education classes lasting 10 weeks.
Study NCT05341544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasym device
Description: The study will utilize the Parasym device (Parasym Health, London, United Kingdom) paired with compatible electrodes to administer the transcutaneous LLTS.
Study NCT05341544 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: Sham device
Study NCT03994471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght
Description: XyloCore Low Strenght: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore Medium Strenght: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore High Strenght: 2.0% Xylitol, 1.5% Glucose, and 0.02% L-carnitine
Study NCT03994471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution
Description: Physioneal 35 or 40 (including Clear-Flex bag), Fixioneal 35 or 40, Dianeal or Dianeal Low Calcium have 1.36%, 2.27% or 3.86% glucose; Balance, Bicavera, Bicanova or Equibalance have 1.25%, 2.3%, 4.5% glucose.
Study NCT05594810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + Addiction focussed - eye movement desensitization and reprocessing (AF-EMDR)
Description: A total of six 45-90 min. sessions of AF-EMDR therapy with an average frequency of twice per week added to a SCP embedded in CRA. AF-EMD therapy consists of a rationale, installating a treatment goal, desensitasing mental video's, installation of positive cognition, future template and positive ending.
Study NCT05594810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU only: Community Reinforcement Approach (CRA) + SCP
Description: CRA is a comprehensive cognitive behavioural treatment that focuses on helping people discover and adopt a pleasurable, social and healthy lifestyle that is more rewarding than a lifestyle including substance use.~Within CRA a regular smoking cessation program is embedded.
Study NCT05594810 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU only: Community Reinforcement Approach (CRA) + SCP
Description: CRA is a comprehensive cognitive behavioural treatment that focuses on helping people discover and adopt a pleasurable, social and healthy lifestyle that is more rewarding than a lifestyle including substance use.~Within CRA a regular smoking cessation program is embedded.
Study NCT05753293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercise
Description: Buteyko breathing technique developed to control hyperventilation and anxiety which leads to shortness of breath. It uses series of exercises to teach patients to breathe less deeply and less rapidly /Bhastrika Bellow Breathing is diaphragmatic breathing - deep breathing involving the diaphragm rather than the accessory muscles. Regulated pranayama exercises require inhalation, maintaining isometric contraction of respiratory muscles and forceful expiration. These techniques will strengthen respiratory muscles
Study NCT06313723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal education management delivered via podcast
Description: Pregnant women assigned to the intervention group (52) will be listened to podcasts on a Samsung Galaxy J7 Prime brand phone while undergoing a 20-minute NST procedure
Study NCT05153954 — intervention group
Intervention type: OTHER
Intervention: Quantitative Indocyanine Green Fluorescence Angiography
Description: Quantitative analyse of ICG around the proximal/oral part of the anastomosis pre-formation of the primary anasomosis
Study NCT06645067 — intervention group
Intervention type: BEHAVIORAL
Intervention: Measuring energy balance
Description: The exercise intervention will consist of a personalized and supervised program lasting 12 weeks with two sessions per week, held on Tuesdays and Thursdays at the Sports and Medicine Center SPORMED in Rennes, France.~Each session will combine endurance and resistance training, commencing with a 6-minute cardiovascular warm-up on ergometers (cycling ergometer or treadmill). This will be followed by 20 minutes at moderate intensity (60-70% of Heart Rate Reserve (HRR)), concluding with a 2-minute recovery period at light intensity. We will measure the resting ED at the start of the programme and the ED during moderate aerobic exercise in the 5th week of APA.
Study NCT05636436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose Recombinant Herpes Zoster Vaccine (CHO cells)
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.
Study NCT06643910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single drug group A
Description: 9x10\^10 BST08 cells, Intravenous infusion，3 subject is planned to be enrolled
Study NCT06643910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined treatment group B
Description: 9x10\^10 BST08 cells+ Pembrolizumab Injection，200mg，Q3W, Intravenous infusion，6subject is planned to be enrolled
Study NCT06643182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Back Support
Description: When the sandbag is to be left by the researcher together with the nurse caring for the patient, the patient will be placed in the left lateral position for a short time, a gel-filled orthopedic non-sweating viscose pillow will be placed in the patient's lumbar region and the patient will be placed in a supine position with the head supported.
Study NCT06645262 — intervention group
Intervention type: OTHER
Intervention: Cryotherapy
Description: cryotherapy, therapeutic exercises, the use of braces, and the Bowen technique.
Study NCT06645405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI algorithm
Description: Artificial intelligence algorithms in the automated reconstruction of intracranial large vessel occlusion (LVO)
Study NCT05548920 — intervention group
Intervention type: OTHER
Intervention: Ultrasound guided Superior Vena Cava Collapsibility Index
Description: Preoperative Ultrasound guided Superior Vena Cava Collapsibility Index will be measured
Study NCT05548920 — intervention group
Intervention type: OTHER
Intervention: Inferior Vena Cava Collapsibility Index
Description: Preoperative Inferior Vena Cava Collapsibility Index will be measured.
Study NCT05636436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose Recombinant Herpes Zoster Vaccine (CHO cells)
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.
Study NCT05636436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose adjuvant
Description: 0.5 mL per dose, containing low dose MA105 adjuvant.
Study NCT04608682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: The muscle relaxant infusion will be discontinued and a bolus of sugammadex (2mg/kg) will be given while performing TceMEPs.
Study NCT04608682 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: The muscle relaxant infusion will be discontinued and 2ml saline will be infused, TceMEPs monitoring will be performed 5 minutes later.
Study NCT05636436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose adjuvant
Description: 0.5 mL per dose, containing high dose MA105 adjuvant.
Study NCT05636436 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive control
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
Study NCT05636436 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL per dose, containing 4.5 mg sodium chloride.
Study NCT06299605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan-Amoxicillin-Tetracycline-Bismuth quadruple regimen for 14 days
Description: Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid + Bismuth 220mg bid for 14 days
Study NCT06299605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan-Amoxicillin-Tetracycline triple regimen for 14 days
Description: Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 14 days
Study NCT06299605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan-Amoxicillin-Tetracycline triple regimen for 7 days
Description: Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 7 days
Study NCT05493722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PS and OS stimulation order 1
Description: PS, OS, OS
Study NCT05493722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PS and OS stimulation order 2
Description: OS, PS, OS
Study NCT05493722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PS and OS stimulation order 3
Description: OS, OS, PS
Study NCT05929807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon CNP
Description: TransCon CNP drug product is a lyophilized powder in a single-use vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
Study NCT06402435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lvonescimab (AK112)
Description: 8Gy\*3 SBRT (continuous irradiation) to irradiate the primary lesion (without axillary lymph node metastasis) or 6Gy\*3 SBRT (continuous irradiation) irradiation to irradiate the primary lesion and axillary lymph node metastasis will be administered at first. And then the first cycle of chemotherapy+AK112 given within 24 hours of the end of SBRT. The total eight cycles of preoperative chemotherapy combined with immunotherapy were administered. Surgical resection was performed within 4-6 weeks after the completion of the eighth cycle of chemotherapy combined with immunotherapy. The chemotherapy regimen consisted of: Four cycles of doxorubicin 50mg/m2 (Q3W) + cyclophosphamide 600mg/m2 (Q3W) were administered, followed by four cycles of sequential albumin paclitaxel (125 mg/m2, d1, d8) for 4 cycles. The immunotherapy drug used was Lvonescimab (AK112).
Study NCT06313684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Initial Assessment
Description: Initial Assessment includes all those necessary to prescribe exercise training, as well as dietary and adherence promotion interventions.~* Functional capacity with 6MWT~* Assessment of skeletal muscle strength, flexibility, and balance.~* Assessment of function~* Assessment of dietary habits~* Assessment of self-efficacy and barriers to CR adherence.~* Screening for depression.
Study NCT06313684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous evaluation
Description: Evaluations during the course of the program will be carried out to inform the progression through the CR stages, the intensity of training and education needs.
Study NCT06313684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Exercise
Description: High-intensity interval training prescribed by physical therapist:~* According to an adapted Wisloff protocol.~* Borg scale to monitor intensity.~* Training 3 times per week.
Study NCT06313684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial support
Description: Based on social-cognitive theory, with self-efficacy as a focus:~* Face-to-face sessions in the first stage of the program: Education, self-monitoring and motivational interview.~* Face-to-face session in the second stage of the program: promoting behavior changes by self-control and self-monitoring~* Regular communication with patients will be supported by the use of mobile devices during the third and fourth stages of program.
Study NCT05504746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHEN26 capsule
Description: Specification: 50mg/capsule and 200mg/capsule. Participants will receive SHEN26 capsule(s) orally for a single dose.~The specification of 50mg/capsule will only be used for the 50mg dose group in the SAD part. For the other dose groups and other parts of the study, 200mg/capsule will be used.
Study NCT05504746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHEN26 capsule
Description: Specification: 200mg/capsule. Participants will receive SHEN26 capsules orally for Q12h X 5.5 days.
Study NCT05504746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHEN26 placebo
Description: Placebo matching the SHEN26 capsule. Specification: 50mg/capsule and 200mg/capsule.~Participants will receive SHEN26 placebo orally for a single dose.
Study NCT05707936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline Flush 20 ml
Description: Normal Saline Flush 20 ml
Study NCT06313684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet management
Description: A dietary plan supported by a nutritionist will be made together with the patient.
Study NCT06313684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Resistance exercises:~* With TheraBand.~* Intensity according to the perceived exertion scale~* Twice a week.
Study NCT06313684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise
Description: Resistance exercises:~* With TheraBand.~* Intensity according to the perceived exertion scale~* Twice a week.
Study NCT06313684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous exercise
Description: Moderate-intensity continuous exercise prescribed by physical therapist :~* The intensity will be moderate, as tolerated~* Borg scale to monitor intensity.~* Frequency of training of 1 to 3 times per week, until completed 20 sessions in 10-12 weeks.
Study NCT06313684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Initial Assessment
Description: Includes all those necessary to plan exercise training, as usual:~* Functional capacity with 6MWT.~* Assessment of skeletal muscle strength.
Study NCT05707936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline Flush 10 ml
Description: Normal Saline Flush 10 ml
Study NCT05707936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Flush (1000 USP, 10ml)
Description: Heparin Flush (1000 USP, 10ml)
Study NCT05721157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-enabled Chest X-ray-based Screening Tool
Description: Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-Chest X-ray result was positive or negative.The system will send a message to corresponding physicians if positive finding.
Study NCT05504746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHEN26 placebo
Description: Placebo matching the SHEN26 capsule. Specification: 200mg/capsule.~Participants will receive SHEN26 placebo orally for Q12h X 5.5 days.
Study NCT06225544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumasiran
Description: Subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
Study NCT06225544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride (placebo)
Description: Placebo, subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
Study NCT05036772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The experimental arm will have the possibility to use a distracting virutel environment for the duration of hysterosalpingography.
Study NCT06240455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WP1302
Description: Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
Study NCT05032235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Normal Renal Function:A single oral dose of Fluzoparib will be administered.
Study NCT05032235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Mild Renal Impairment:A single oral dose of Fluzoparib will be administered.